These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Taylor M; Moore S; Mayes J; Parkin E; Beeg M; Canovi M; Gobbi M; Mann DM; Allsop D Biochemistry; 2010 Apr; 49(15):3261-72. PubMed ID: 20230062 [TBL] [Abstract][Full Text] [Related]
7. Inhibitors of protein aggregation and toxicity. Amijee H; Madine J; Middleton DA; Doig AJ Biochem Soc Trans; 2009 Aug; 37(Pt 4):692-6. PubMed ID: 19614577 [TBL] [Abstract][Full Text] [Related]
8. Protective effects of [Gly14]-Humanin on beta-amyloid-induced PC12 cell death by preventing mitochondrial dysfunction. Jin H; Liu T; Wang WX; Xu JH; Yang PB; Lu HX; Sun QR; Hu HT Neurochem Int; 2010 Feb; 56(3):417-23. PubMed ID: 19941922 [TBL] [Abstract][Full Text] [Related]
9. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation. Takahashi T; Mihara H Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396 [TBL] [Abstract][Full Text] [Related]
10. PP1 inhibition by Abeta peptide as a potential pathological mechanism in Alzheimer's disease. Vintém AP; Henriques AG; da Cruz E Silva OA; da Cruz E Silva EF Neurotoxicol Teratol; 2009; 31(2):85-8. PubMed ID: 19028567 [TBL] [Abstract][Full Text] [Related]
11. Protective effect of colostrinin on neuroblastoma cell survival is due to reduced aggregation of beta-amyloid. Schuster D; Rajendran A; Hui SW; Nicotera T; Srikrishnan T; Kruzel ML Neuropeptides; 2005 Aug; 39(4):419-26. PubMed ID: 15890402 [TBL] [Abstract][Full Text] [Related]
12. Alzheimer's Abeta peptides containing an isostructural backbone mutation afford distinct aggregate morphologies but analogous cytotoxicity. Evidence for a common low-abundance toxic structure(s)? Bieschke J; Siegel SJ; Fu Y; Kelly JW Biochemistry; 2008 Jan; 47(1):50-9. PubMed ID: 18078350 [TBL] [Abstract][Full Text] [Related]
13. Potential lead for an Alzheimer drug: a peptide that blocks intermolecular interaction and amyloid beta protein-induced cytotoxicity. Kwak JW; Kim HK; Chae CB J Med Chem; 2006 Aug; 49(16):4813-7. PubMed ID: 16884292 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of cytotoxicity and amyloid fibril formation by a D-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide. Wiesehan K; Stöhr J; Nagel-Steger L; van Groen T; Riesner D; Willbold D Protein Eng Des Sel; 2008 Apr; 21(4):241-6. PubMed ID: 18252750 [TBL] [Abstract][Full Text] [Related]
15. Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide. Austen BM; Paleologou KE; Ali SA; Qureshi MM; Allsop D; El-Agnaf OM Biochemistry; 2008 Feb; 47(7):1984-92. PubMed ID: 18189413 [TBL] [Abstract][Full Text] [Related]
16. Folding and membrane insertion of amyloid-beta (25-35) peptide and its mutants: implications for aggregation and neurotoxicity. Tsai HH; Lee JB; Tseng SS; Pan XA; Shih YC Proteins; 2010 Jun; 78(8):1909-25. PubMed ID: 20229606 [TBL] [Abstract][Full Text] [Related]
17. A two-step strategy for structure-activity relationship studies of N-methylated aβ42 C-terminal fragments as aβ42 toxicity inhibitors. Li H; Zemel R; Lopes DH; Monien BH; Bitan G ChemMedChem; 2012 Mar; 7(3):515-22. PubMed ID: 22307963 [TBL] [Abstract][Full Text] [Related]
18. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231 [TBL] [Abstract][Full Text] [Related]
19. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Schlenzig D; Manhart S; Cinar Y; Kleinschmidt M; Hause G; Willbold D; Funke SA; Schilling S; Demuth HU Biochemistry; 2009 Jul; 48(29):7072-8. PubMed ID: 19518051 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue. Bodles AM; El-Agnaf OM; Greer B; Guthrie DJ; Irvine GB Neurosci Lett; 2004 Apr; 359(1-2):89-93. PubMed ID: 15050719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]